Otter Health has launched with $8 million in seed funding to address one of healthcare's most contentious administrative processes: deciding whether medical treatment is necessary and should be covered.
The round was co-led by Fika Ventures and Evidenced, with participation from Slow Ventures, Metrodora, CoFound Partners, Layout Ventures, Patient Capital and Semper Virens. The company is led by co-founder and CEO Keith Florance.
Traditional utilization management relies heavily on prior authorization, requiring healthcare providers to obtain insurer approval before delivering certain treatments. The process is intended to control unnecessary spending, but it frequently introduces delays and administrative costs.
Otter proposes a different system. Its AI-powered, electronic-health-record-agnostic platform continuously evaluates clinical decisions against medical evidence and treatment guidelines. Rather than requiring authorization for individual procedures, the software gives insurers and healthcare providers a shared view of whether care aligns with established clinical standards.
The platform covers referrals, outpatient procedures, treatment pathways and care transitions. It also provides peer comparisons and targeted feedback to clinicians.
Otter says it is already working with multiple payer and provider organizations. The company reports that, in implementations replacing traditional authorization with its platform and clinical engagement, decisions inconsistent with evidence-based guidelines have fallen below 5%. Those results have not been independently validated in the announcement.
The problem extends beyond paperwork. Insurers want to reduce unnecessary spending, while physicians are concerned that cost-control systems can interfere with clinical judgment. According to American Medical Association survey data cited by Otter, 93% of physicians report that prior authorization delays necessary care.
Otter's challenge will be demonstrating that its system can identify genuinely low-value care without introducing another form of automated gatekeeping. Long-term adoption will depend on measurable patient outcomes, clinician trust and whether both insurers and providers can agree on how medical appropriateness should be assessed.